default_app_config = 'providers.gov.clinicaltrials.apps.AppConfig'

"""
XML Schema for ClinicalTrials.gov public XML
http://clinicaltrials.gov/ct2/html/images/info/public.xsd

Example record:
<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 01, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951182</url>
  </required_header>
  <id_info>
    <org_study_id>VX15-440-101</org_study_id>
    <secondary_id>2016-000454-36</secondary_id>
    <nct_id>NCT02951182</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo- and active-controlled, parallel group,
      multicenter study to evaluate the safety, tolerability, and efficacy of VX-440 in dual and
      triple combination with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects
      with cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF
      transmembrane conductance regulator (CFTR) gene (F508del/F508del), or who are heterozygous
      for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to
      TEZ and/or IVA therapy (F508del/MF).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>from baseline up to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in sweat chloride concentrations</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in ppFEV1</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pulmonary exacerbations</measure>
    <time_frame>through Week 12 (12-week cohort only)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first pulmonary exacerbation</measure>
    <time_frame>through Week 12 (12-week cohort only)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body mass index (BMI)</measure>
    <time_frame>from baseline at Week 12 (12-week cohort only)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in BMI z-score</measure>
    <time_frame>from baseline at Week 12 (12-week cohort only)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in weight</measure>
    <time_frame>from baseline at Week 12 (12-week cohort only)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of VX-152, TEZ, M1-TEZ, IVA, and M1-IVA (&#956;g/mL)</measure>
    <time_frame>from Day 1 through Day 43 (4-week cohorts), and through Week 12 (12-week cohort)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve during a dosing interval (AUCtau) of VX-152, TEZ, M1-TEZ, IVA, and M1-IVA (&#956;g.h/mL)</measure>
    <time_frame>from Day 1 through Day 43 (4-week cohorts), and through Week 12 (12-week cohort)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed pre-dose concentration (Ctrough) of VX-152, TEZ, M1-TEZ, IVA, and M1-IVA (&#956;g/mL)</measure>
    <time_frame>from Day 1 through Day 43 (4-week cohorts), and through Week 12 (12-week cohort)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A:Triple Combination(TC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VX-440 200 milligram (mg) administered every 12 hours (q12h). TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.
Morning Dose: VX-440 + TEZ/IVA
Evening Dose: VX-440 + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A: Triple Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos matched to VX-440, TEZ/IVA, and IVA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B TC-High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
The dosage of VX-440 may be adjusted based on data from Cohort A.
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B:TC-Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
Placebo matched to VX-440
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 4- week Cohort B: Triple Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
Placebos matched to VX-440, TEZ, and IVA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TC- High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after the Cohort A blinded review, if supported by safety and PK data.
The dosage of VX-440 may be adjusted based on data from Cohort A.
Placebo matched to morning TEZ/IVA.
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA
The treatment period will be preceded by a 4-week run-in period and followed by a 4-week washout period, during both of which subjects will receive:
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TEZ/IVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
Placebos matched to VX-440, evening TEZ, and morning IVA.
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.
Morning Dose: TEZ/IVA
Evening Dose: IVA
The treatment period will be preceded by a 4-week run-in period and followed by a 4-week washout period, during both of which subjects will receive:
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Placebo matched to VX-440
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual IVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Placebo matched to TEZ.
Morning Dose: VX-440 + IVA
Evening Dose: VX-440 + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual TEZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Placebo matched to IVA
Morning Dose: VX-440 + TEZ
Evening Dose: VX-440 + TEZ
VX-440 administered in combination with TEZ q12h and placebo matched IVA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Triple Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
Placebos matched to VX-440, TEZ, and IVA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tezacaftor</intervention_name>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A:Triple Combination(TC)</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B:TC-Low</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TC- High</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TEZ/IVA</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-Low</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual TEZ</arm_group_label>
    <other_name>TEZ</other_name>
    <other_name>VX-661</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor</intervention_name>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A:Triple Combination(TC)</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B:TC-Low</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TC- High</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TEZ/IVA</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-Low</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual IVA</arm_group_label>
    <other_name>IVA</other_name>
    <other_name>VX-770</other_name>
    <other_name>Kalydeco</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-440</intervention_name>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A:Triple Combination(TC)</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B:TC-Low</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TC- High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-Low</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual IVA</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual TEZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched Placebos</intervention_name>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A: Triple Placebo</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B:TC-Low</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4- week Cohort B: Triple Placebo</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TC- High</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TEZ/IVA</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-Low</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual IVA</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual TEZ</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Triple Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to comply with scheduled visits, treatment plan, study restrictions,
             laboratory tests, contraceptive guidelines, and other study procedures.

          -  To prevent pregnancy, female participants of childbearing potential and their male
             partners will be required to use pre-specified, highly effective methods of
             non-hormonal contraception. Male participants with female partners of childbearing
             potential will be required to use a condom.

          -  Body weight &#8805;35 kg.

          -  Sweat chloride value &#8805;60 mmol/L from test results obtained during screening.

          -  Subjects must have an eligible CFTR genotype:

               -  Heterozygous for F508del and a minimal function (MF) mutation known or predicted
                  not to be responsive to TEZ and/or IVA.

               -  Homozygous for F508del

          -  Subjects must have an FEV1 &#8805;40% and &#8804;90% of predicted normal for age, sex, and height
             at the Screening Visit

          -  Stable CF disease as judged by the investigator.

          -  Willing to remain on a stable CF medication regimen through the planned end of
             treatment or, if applicable, the Safety Follow up Visit.

        Exclusion Criteria:

          -  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to
             the subject.

          -  History of cirrhosis with portal hypertension.

          -  Risk factors for Torsade de Pointes

          -  History of hemolysis.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening.

          -  Clinically significant abnormal laboratory values at screening

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy for pulmonary disease within 28 days before the first dose of study drug.

          -  Lung infection with organisms associated with a more rapid decline in pulmonary
             status

          -  An acute illness not related to CF within 14 days before the first dose of study drug

          -  A standard digital ECG demonstrating QTc &gt;450 msec at screening.

          -  History of solid organ or hematological transplantation.

          -  History or evidence of cataract or lens opacity determined to be clinically
             significant by the ophthalmologist or optometrist based on the ophthalmologic
             examination during the Screening Period.

          -  History of alcohol or drug abuse in the past year, including but not limited to,
             cannabis, cocaine, and opiates, as deemed by the investigator.

          -  Ongoing or prior participation in an investigational drug study, with certain
             exceptions. (e.g., ongoing participation in NCT02565914)

          -  Use of commercially available CFTR modulator (e.g., Kalydeco, Orkambi) within 14 days
             before screening (applies only to the Heterozygous F508del/MF cohorts; does not apply
             to the Homozygous F508del/F508del Cohort).

          -  Pregnant or nursing females: Females of childbearing potential must have a negative
             pregnancy test at screening and Day 1.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>617-341-6777</phone>
    <email>medicalinfo@vrtx.com</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 28, 2016</lastchanged_date>
  <firstreceived_date>October 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
"""
